Zum Inhalt springen

Forschungsgruppe Klinische Psychopharmakologie

Forschungsschwerpunkte

Management von Nebenwirkungen und Rezidivrisiken

Aktuelle Projekte

  • Combine - A randomized-controlled trial to assess the benefits of olanzapine and amisulpride combination treatment in acutely ill schizophrenia patients.
  • SWITCH - Efficacy of early anti-psychotic switch versus maintenance in patients with schizophrenia poorly responding to two weeks of antipsychotic treatment
  • NeSSy - Clinical effectiveness of the newer antipsychotic compounds olanzapine, quetiapine and aripiprazole in comparison with low dose conventional antipsychotics (haloperidol and flupentixol) in patients with schizophrenia

Ausgewählte Publikationen

  • Cordes J, Thünker J, Agelink MW, Kahl KG, Gaebel W, Klimke A, Hauner H. Effect of a preventive weight-management program in schizophrenic patients treated with Olanzapine. The World Journal of Biological Psychiatry. Accepted 05/2011.
  • Cordes J, Larisch R, Henning U, Thünker J, Werner C, Orozco G, Mayoral F, Rivas F, Auburger G, Tosch M, Rietschel M, Gaebel W, Müller HW, Klimke A. Abnormal neuroendocrine response to clomipramine in hereditary affective psychosis. Depression and Anxiety 2009, 26(8) E111-9.
  • Lange-Asschenfeldt C, Grohmann R, Lange-Asschenfeldt B, Engel R, Rüther E, Cordes J. Cutaneous Adverse Reactions to Psychotropic Drugs: Data from the AMSP Multicenter Surveillance Program. The Journal of Clinical Psychiatry 2009, 70(9): 1258-65.

Das Team

Wissenschaftliche Mitarbeiter

  • Dipl.-Psych. Mathias Riesbeck

Nach oben

Kooperationen

...